Azafaros has licensed intellectual property from Leiden University and Amsterdam UMC's Academic Medical Centre to target lysosomal storage disorders.
Azafaros, a Netherlands-based metabolic disorder therapy spinout from Leiden University and Amsterdam UMC’s Academic Medical Centre, closed a founding seed round on Monday backed by VC firm BioGeneration Ventures (BGV).
Azafaros has licensed assets from both institutions to develop oral azasugar-based compounds to combat lysosomal storage disorders (LSD), a group of rare metabolic diseases that currently have no effective cure.
The compounds target the metabolism of malformed glycolipids in the LSD patient to impede the disorder’s pathological impact. Azasugar is…
